E
CLPT icon

Ergoteles’s ClearPoint Neuro CLPT Stock Holding History

Ergoteles’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-71,322
Closed -$739K – 1510
2022
Q3 		$739K Sell
71,322
-20,178
-22% -$266K 0.03% 612
2022
Q2 		$1.19M Buy
+91,500
New +$935K 0.04% 471

Other funds holding CLPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ergoteles's CLPT Position: Q4 2022 in Review

Ergoteles sold out of ClearPoint Neuro (CLPT) in Q4 2022, closing a stake of 71,322 shares — an estimated $739K sold.

Ergoteles first reported a position in CLPT in Q2 2022 and held it in 2 quarters. The position peaked at $1.19M in Q2 2022. 62 funds tracked by Wall St. Rank hold CLPT as of Q4 2022.

  • Ergoteles reported no remaining ClearPoint Neuro position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 71,322 ClearPoint Neuro shares in Q4 2022, an estimated $739K.
  • Ergoteles first reported a position in ClearPoint Neuro in Q2 2022 and held it in 2 quarters.
  • Ergoteles's ClearPoint Neuro position peaked at $1.19M in Q2 2022.
  • 62 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.